Evidence map›Paper›PMID 41704157›Full record

ArticleInternational journal of cancer2026

Oxaliplatin-induced neuropathy after total neoadjuvant therapy for rectal cancer: Dose-response relationship and impact on quality of life.

Georg W Wurschi, Andreas Hinz, Melanie Schneider, Jan-Niklas Becker, Bernd Frerker, Samuel M Vorbach, Felix Ehret, Markus Diefenhardt, Fabian Schunn, Maria-Elena von Gruben and 20 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Georg W WurschiDepartment of Radiotherapy and Radiation Oncology, Jena University Hospital, Jena, Germany.ORCID https://orcid.org/0000-0002-8751-9862
Andreas HinzDepartment of Medical Psychology and Medical Sociology, University Medical Center Leipzig, Leipzig, Germany.
Melanie SchneiderDepartment of Radiotherapy and Radiation Oncology, Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Jan-Niklas BeckerDepartment of Radiotherapy, Hannover Medical School, Hannover, Germany.
Bernd FrerkerDepartment of Radiotherapy and Radiation Oncology, Rostock University Medical Center, Rostock, Germany.
Samuel M VorbachDepartment of Radiation Oncology, Medical University of Innsbruck, Innsbruck, Austria.
Felix EhretCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Radiation Oncology, Berlin, Germany.ORCID https://orcid.org/0000-0001-6177-1755
Markus DiefenhardtDepartment of Radiotherapy and Oncology, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany.
Fabian SchunnDepartment of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Maria-Elena von GrubenDepartment of Radiotherapy and Radiation Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Marcel BüttnerDepartment of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany.
Elgin HoffmannDepartment of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany.
Alexander RühleComprehensive Cancer Center Central Germany (CCCG), Partner Site Leipzig, Leipzig, Germany.
Josephine BeierComprehensive Cancer Center Central Germany (CCCG), Partner Site Leipzig, Leipzig, Germany.
Simone FerdinandusDepartment of Radiation Oncology, Cyberknife and Radiotherapy, Faculty of Medicine and University Hospital Cologne, Köln, Germany.
Maike TrommerDepartment of Radiation Oncology, Cyberknife and Radiotherapy, Faculty of Medicine and University Hospital Cologne, Köln, Germany.
Ezgi Ceren SahinDepartment of Radiotherapy, West German Cancer Center, University Hospital Essen, Essen, Germany.
Julian HlouschekDepartment of Radiotherapy, West German Cancer Center, University Hospital Essen, Essen, Germany.
Kynann AnindithaDepartment of Radiooncology, Klinikum Stuttgart, Stuttgart, Germany.
Daphne Schepers von OhlenDepartment of Radiotherapy, University Medical Center Schleswig-Holstein/Lübeck, Lübeck, Germany.
Justus KaufmannDepartment of Radiooncology, University Medical Center of the Johannes-Gutenberg-University Mainz, Mainz, Germany.
Alina DepardonDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Hai Minh HaDepartment of Radiation Oncology, Otto von Guericke Universität Magdeburg, Magdeburg, Germany.
Christopher KesslerDepartment of Radiation Oncology, Technical University of Munich (TUM), School of Medicine and Klinikum Rechts der Isar, München, Germany.
Adrianna CieslakDepartment of Radiation Oncology, University Medicine Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Simon TrommerDepartment for Radiotherapy, University Hospital Halle, Halle (Saale), Germany.
Alexander FabianDepartment of Radiation Oncology, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany.ORCID https://orcid.org/0000-0003-2415-527X
Florian RißnerCenter for Clinical Studies, Jena University Hospital, Jena, Germany.
Maximilian RömerDepartment of Radiotherapy and Radiation Oncology, Jena University Hospital, Jena, Germany.
Klaus PietschmannDepartment of Radiotherapy and Radiation Oncology, Jena University Hospital, Jena, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxaliplatin-based regimens are increasingly used in total neoadjuvant therapy (TNT) for locally advanced rectal cancer, frequently causing dose-limiting chemotherapy-induced peripheral neuropathy (CIPN), whose extent and impact on health-related quality of life (HrQoL) remain insufficiently characterized. The optimal duration and intensity of chemotherapy within TNT for tumor response and toxicity remain unclear. This retrospective multicenter study (DRKS00033000) assessed the dose-response relationship of CIPN with cumulative oxaliplatin dose (cOXAd) and its impact on HrQoL. A total of 227 patients (164 men) with a median age of 63 (Q1-Q3: 54-68) years, who underwent oxaliplatin-based TNT between 2015 and 2024, were analyzed. HrQoL was assessed cross-sectionally during follow-up using the EORTC QLQ-C30 and QLQ-CIPN20 questionnaires. Multivariable logistic regression was applied to evaluate the relationship between cOXAd and CIPN grade ≥2, and known-group comparisons examined differences in HrQoL scores. At follow-up, 61 patients (26.9%) experienced CIPN grade ≥2 after a median cOXAd of 758.8 mg/m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsNeoadjuvant TherapyOxaliplatinPeripheral Nervous System DiseasesQuality of LifeRectal NeoplasmsAgedCross-Sectional StudiesDose-Response Relationship, DrugFemaleFluorouracilHumansMaleMiddle AgedRetrospective StudiesFluorouracilOxaliplatinCIPNoxaliplatinpolyneuropathyrectal cancertotal neoadjuvant therapy

Identifiers

PMID41704157
PMCPMC13140008

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.